Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
64
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$190.02
Seasonality move
:
-0.64%
Day range:
$188.30 - $198.00
52-week range:
$95.49 - $198.00
Dividend yield:
0%
P/E ratio:
15.09x
P/S ratio:
2.74x
P/B ratio:
2.66x
Volume:
1.9M
Avg. volume:
1.1M
1-year change:
31.07%
Market cap:
$11.5B
Revenue:
$4.3B
EPS (TTM):
-$5.97
Analysts' Opinion
-
Consensus RatingJazz Pharmaceuticals Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $222.53, Jazz Pharmaceuticals Plc has an estimated upside of 17.76% from its current price of $188.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $188.00 representing 0.51% downside risk from its current price of $188.97.
Fair Value
-
According to the consensus of 11 analysts, Jazz Pharmaceuticals Plc has 17.76% upside to fair value with a price target of $222.53 per share.
JAZZ vs. S&P 500
-
Over the past 5 trading days, Jazz Pharmaceuticals Plc has overperformed the S&P 500 by 11.44% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Jazz Pharmaceuticals Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Jazz Pharmaceuticals Plc has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Jazz Pharmaceuticals Plc reported revenues of $1.2B.
Earnings Growth
-
Jazz Pharmaceuticals Plc has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Jazz Pharmaceuticals Plc reported earnings per share of $3.21.
Enterprise value:
14.5B
EV / Invested capital:
1.48x
Price / LTM sales:
2.74x
EV / EBIT:
24.98x
EV / Revenue:
3.39x
PEG ratio (5yr expected):
0.28x
EV / Free cash flow:
12.17x
Price / Operating cash flow:
9.83x
Enterprise value / EBITDA:
11.34x
Gross Profit (TTM):
$3.1B
Return On Assets:
-3.1%
Net Income Margin (TTM):
-8.35%
Return On Equity:
-8.79%
Return On Invested Capital:
-3.7%
Operating Margin:
21.25%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $3.8B | $4.1B | $4.3B | $1.1B | $1.2B | |
| Gross Profit | $2.8B | $3B | $3.1B | $800.6M | $874.7M | |
| Operating Income | $659.3M | $726.6M | $579.1M | $190.8M | $254.5M | |
| EBITDA | $1.3B | $1.4B | $1.3B | $359.2M | $433.7M | |
| Diluted EPS | $5.77 | $8.70 | -$5.97 | $3.11 | $3.21 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.6B | $2.5B | $3.3B | $4.6B | $4.2B | |
| Total Assets | $12.3B | $10.8B | $11.4B | $12B | $11.7B | |
| Current Liabilities | $809.3M | $933.2M | $1.5B | $1B | $2.2B | |
| Total Liabilities | $8.3B | $7.7B | $7.7B | $7.9B | $7.3B | |
| Total Equity | $4B | $3.1B | $3.7B | $4.1B | $4.3B | |
| Total Debt | $6.1B | $5.8B | $5.8B | $6.2B | $5.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.1B | $1.4B | $1.4B | $398.6M | $362.5M | |
| Cash From Investing | -$163.1M | -$508.2M | -$1.5B | -$193.3M | -$372.2M | |
| Cash From Financing | -$305.3M | $20.5M | -$873.4M | -$8.3M | $75.4M | |
| Free Cash Flow | $1.1B | $1.4B | $1.2B | $385.3M | $292.3M | |
JAZZ
Sector
Market Cap
$11.5B
$25.8M
Price % of 52-Week High
95.44%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
1.67%
-1.64%
1-Year Price Total Return
31.07%
-18.88%
Beta (5-Year)
0.260
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$176.42
200-day SMA
Buy
Level
$137.94
Bollinger Bands (100)
Buy
Level
143.53 - 175.57
Chaikin Money Flow
Buy
Level
34.4M
20-day SMA
Buy
Level
$169.89
Relative Strength Index (RSI14)
Buy
Level
70.25
ADX Line
Buy
Level
18.89
Williams %R
Neutral
Level
-24.6587
50-day SMA
Buy
Level
$168.92
MACD (12, 26)
Buy
Level
4.42
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
226M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6985)
Sell
CA Score
(Annual)
Level (-0.702)
Buy
Beneish M-Score
(Annual)
Level (-2.8149)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.0463)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Stock Forecast FAQ
In the current month, JAZZ has received 9 Buy ratings 2 Hold ratings, and 0 Sell ratings. The JAZZ average analyst price target in the past 3 months is $222.53.
-
Where Will Jazz Pharmaceuticals Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Jazz Pharmaceuticals Plc share price will rise to $222.53 per share over the next 12 months.
-
What Do Analysts Say About Jazz Pharmaceuticals Plc?
Analysts are divided on their view about Jazz Pharmaceuticals Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jazz Pharmaceuticals Plc is a Sell and believe this share price will drop from its current level to $188.00.
-
What Is Jazz Pharmaceuticals Plc's Price Target?
The price target for Jazz Pharmaceuticals Plc over the next 1-year time period is forecast to be $222.53 according to 11 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is JAZZ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Jazz Pharmaceuticals Plc is a Buy. 9 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of JAZZ?
You can purchase shares of Jazz Pharmaceuticals Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jazz Pharmaceuticals Plc shares.
-
What Is The Jazz Pharmaceuticals Plc Share Price Today?
Jazz Pharmaceuticals Plc was last trading at $190.02 per share. This represents the most recent stock quote for Jazz Pharmaceuticals Plc. Yesterday, Jazz Pharmaceuticals Plc closed at $188.97 per share.
-
How To Buy Jazz Pharmaceuticals Plc Stock Online?
In order to purchase Jazz Pharmaceuticals Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get JAZZ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
JAZZ
Sector
P/E ratio
15.09x
23.44x
PEG ratio
0.28x
-0.01x
P/B ratio
2.66x
1.81x
Price / LTM sales
2.74x
1.56x
Growth Metrics
JAZZ
Sector
Revenue growth
10.09%
3.27%
Earnings growth
3.22%
9.66%
Revenue (5-year growth)
12.54%
6.43%
Earnings forecast
$6.51
-$0.20
Profitability
JAZZ
Sector
Profitability FY 2025
$3.1B
$2.3M
Return on invested capital
-3.7%
-33.49%
Return on assets
-3.1%
-29.74%
Return on equity
-8.79%
-39.33%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
May
5
Estimated Next Earnings Date
May
26
Balance Sheet
JAZZ
Sector
Total cash
$2.4B
$24.2M
Short term investments
$580M
$23.8M
Total assets
$11.7B
$71.1M
Long term debt
$5.4B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
